melanocortin comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-02-02. Where a claim depends on a specific study, the study is described rather than over-claimed.
Outside the approved product, bremelanotide circulates as a research chemical sold by peptide vendors, often labelled PT-141. Such material is not manufactured under pharmaceutical quality standards, and independent testing has repeatedly found content that differs from the label. Analytical certificates supplied with a purchase are not strong evidence of purity because they are usually generated by the seller. Online discussion tends to blur the distinction between the approved drug and unregulated powder, which complicates interpretation of reported experiences.
PT-141 is the original development code for bremelanotide, a synthetic peptide first studied as a potential tanning and sexual-response agent in the 1990s. Researchers at a small American biotechnology firm designed it as a shortened analogue of melanotan II, which itself came from work on alpha-melanocyte-stimulating hormone. Early screening focused on pigmentation, but behavioural observations in animal models redirected attention toward sexual motivation. That shift made PT-141 one of the first melanocortin compounds investigated specifically for effects on desire rather than on skin colour.
Clinical development proceeded through two routes of administration. An intranasal formulation advanced first, but variable absorption and tolerability problems led to a switch to subcutaneous injection. The United States Food and Drug Administration approved the subcutaneous product in 2019 for hypoactive sexual desire disorder in premenopausal women. Marketing rights subsequently changed hands, and commercial availability has fluctuated since approval. Use in men, in postmenopausal women, and in combination with other agents remains outside the approved label.
Bremelanotide is a moderately large peptide with a molecular mass near 1025 daltons. In lyophilised form it appears as a white to off-white powder and is freely soluble in water and other polar solvents. The intact lactam ring is essential for receptor affinity, while linearised fragments bind far more weakly. Solutions are sensitive to extremes of pH and to prolonged exposure to light and heat, so handling typically involves buffered conditions and cold storage. Its short plasma half-life reflects rapid distribution and clearance rather than chemical breakdown inside the vial.
Development of the peptide passed through several delivery formats, including an intranasal version tested in early trials and an injectable version that entered later clinical study. Regulatory approval for a subcutaneous product in the United States was granted in 2019 after review of controlled trials in premenopausal women. Outside the clinic, the compound circulates in research and non-pharmaceutical markets under its code name, where identity and purity vary considerably between suppliers. Synonyms appearing across technical literature include bremelanotide, PT-141, and Palatin 141.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C50H68N14O10 | Free base; the drug product is formulated as an acetate salt |
| Molar mass | About 1025 g/mol | Calculated for the free base |
| Appearance | White to off-white lyophilized powder | Typical form of research-grade material |
| CAS Registry Number | 189691-06-3 | Common listing for the free base |
| Typical storage | -20 °C, desiccated, protected from light | Repeated freeze-thaw cycles are best avoided |
Bremelanotide is a synthetic cyclic heptapeptide developed under the research code PT-141. The code reflects its position in an internal compound series rather than a chemical classification, and the name bremelanotide was later adopted for regulatory filings. Structurally it belongs to the melanocortin peptide family and shares a core sequence motif with alpha-melanocyte-stimulating hormone. The compound is supplied as an acetate salt in aqueous solution for injection. In reference literature it is indexed under both the code and the generic name, a dual listing that can complicate database searches.
Early work on melanocortin analogs in the 1980s and 1990s produced peptides intended to influence pigmentation and appetite. One of these, melanotan II, was observed to affect sexual desire as an incidental finding in self-administration reports. Researchers then pursued analogs with altered receptor selectivity and improved handling characteristics, and PT-141 emerged from that program in the late 1990s. The development path moved from dermatology and metabolism toward a central nervous system application, a shift that shaped both trial designs and the eventual label.
Bremelanotide is a synthetic cyclic heptapeptide developed as an analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation and appetite signalling. Its structure contains seven amino acid residues joined by a lactam bridge that closes the ring between two side chains. The molecular formula is C50H68N14O10 and the nominal molecular mass is near 1025 daltons. Much of the early laboratory literature refers to the same molecule by the development code PT-141.
The compound emerged from a research programme examining melanocortin analogues for effects on skin pigmentation. During early human studies, participants reported spontaneous erections as an unexpected side effect, which redirected development toward sexual function rather than tanning. An intranasal formulation was investigated in clinical trials but did not reach market approval. A subcutaneous injectable version later completed the regulatory process, and the nasal route does not appear in approved labelling.
Approved use is narrow and jurisdiction-specific. In the United States, the injectable product is authorised for premenopausal women with acquired, generalised hypoactive sexual desire disorder, a diagnosis that requires documented distress. It is not approved for men, for postmenopausal women, or for use alongside hormonal contraceptives under the approved labelling. Outside regulated markets, the same peptide is frequently sold as a research chemical, where identity, purity, and sterility are not independently verified.
=== Signs and symptoms === The classic clinical syndrome for vitamin B6 deficiency is a seborrheic dermatitis-like eruption, atrophic glossitis with ulceration, angular cheilitis, conjunctivitis, intertrigo, abnormal electroencephalograms, microcytic anemia (due to impaired heme synthesis), and neurological symptoms of somnolence, confusion, depression, and neuropathy (due to impaired sphingosine synthesis). In infants, a deficiency in vitamin B6 can lead to irritability, abnormally acute hearing, and convulsive seizures. Less severe cases present with metabolic disease associated with insufficient activity of the coenzyme pyridoxal 5' phosphate (PLP). The most prominent of the lesions is due to impaired tryptophan–niacin conversion. This can be detected based on urinary excretion of xanthurenic acid after an oral tryptophan load. Vitamin B6 deficiency can also result in impaired transsulfuration of methionine to cysteine. The PLP-dependent transaminases and glycogen phosphorylase provide the vitamin with its role in gluconeogenesis, so deprivation of vitamin B6 results in impaired glucose tolerance.
Statue of William E. Dodge (1885), a standing figure located on a pedestal at the park's northern border Statue of J. Marion Sims (1894), removed in the 1930s Washington Irving (1894), removed in the 1930s William Cullen Bryant Memorial (1911), a standing figure located on a canopied pedestal at the park's eastern border Josephine Shaw Lowell Memorial Fountain (1913), located at the park's western border; the fountain collects about $3,000 to $4,000 in coins each year, from dozens of countries Bust of Johann Wolfgang von Goethe (1932), a bust located at the park's southern border Statue of José Bonifácio de Andrada (1954, dedicated 1955), a standing figure located on a pedestal at the park's southwestern corner Statue of Gertrude Stein (1992), a sitting figure located at the park's southeastern corner Statue of Benito Juárez (2002), a standing figure located on a pedestal at the park's northwestern corner
== Research == The minimum dose (5 mg/kg) was confirmed in a clinical trial performed by HTI Bio-services, Inc. It evaluated the effective dose for the treatment of an infected dermal wound. The study included forty-eight mixed breed dogs (both male and female) with weights ranging from 14.5-24.5 kilograms. These dogs were randomly placed into treatment groups. Once wounds were created, the dogs were inoculated with culture both containing both Escherichia coli and Klebsiella pneumoniae. Pertinent observations and measurements were then taken and tabulated. Culture scores were significantly reduced, confirming 5 mg/kg to be an effective dose. Clinical field trials were also performed to evaluate both the efficacy and safety of difloxacin tablets. Clinical signs of bacterial infections were defined in a protocol. Dogs who presented to investigators with these signs were admitted into the study. In total, eighteen veterinarians located in four different geographical areas of the U.S. (Southeast, Midwest, Northwest, and West) conducted these clinical efficacy and safety evaluations.
=== Beyond Meat === In July 2018, A&W locations began serving Beyond Meat's vegan Beyond Burger. The chain had a shortage of the Beyond Burger in August 2018, but announced that all locations would receive stock by October 2018. In 2019 A&W expanded its Beyond Meat offerings with the release of the Beyond Meat Sausage N' Egger.
Sources: en.wikipedia.org
=== Characters === Portal features two prominent characters: the player-controlled silent protagonist named Chell, and GLaDOS (Genetic Lifeform and Disk Operating System), a computer artificial intelligence that monitors and directs the player. In the English-language version, GLaDOS is voiced by Ellen McLain, though her voice has been altered to sound more artificial. The only background information presented about Chell is given by GLaDOS; the credibility of these facts, such as Chell being adopted, an orphan, and having no friends, is questionable at best, as GLaDOS is a liar by her own admission. In the "Lab Rat" comic created by Valve to bridge the gap between Portal and Portal 2, Chell's records reveal she was ultimately rejected as a test subject for having "too much tenacity"—the main reason Doug Rattmann, a former employee of Aperture Science, moved Chell to the top of the test queue.
== Introduction == Membrane technology covers all engineering approaches for the transport of substances between two fractions with the help of semi-permeable membranes. In general, mechanical separation processes for separating gaseous or liquid streams use membrane technology. In recent years, different methods have been used to remove environmental pollutants, like adsorption, oxidation, and membrane separation. Different pollution occurs in the environment like air pollution, waste water pollution etc. As per industry requirement to prevent industrial pollution because more than 70% of environmental pollution occurs due to industries. It is their responsibility to follow government rules of the Air Pollution Control & Prevention Act 1981 to maintain and prevent the harmful chemical release into the environment. Make sure to do prevention & safety processes after that industries are able to release their waste in the environment. Biomass-based Membrane technology is one of the most promising technologies for use as a pollutants removal weapon because it has low cost, more efficiency, & lack of secondary pollutants. Typically polysulfone, polyvinylidene fluoride, and polypropylene are used in the membrane preparation process. These membrane materials are non-renewable and non-biodegradable which create harmful environmental pollution. Researchers are trying to find a solution to synthesize an eco-friendly membrane which avoids environmental pollution.
Bernice Rubens, novelist Miri Rubin (born 1956), historian and Professor of Medieval and Early Modern History at Queen Mary University of London and author of over ten scholarly academic texts and monographs on religion and the Middle Ages; educated at the Hebrew University of Jerusalem and the University of Cambridge; Rubin writes about social and religious history of Europe between 1100 and 1500, concentrating on interactions between public rituals, power, and community life. Oliver Sacks (9 July 1933 – 30 August 2015), neurologist, naturalist, historian of science, and writer of over twenty books, screenplays and scholarly articles, amongst them, 1973 book Awakenings, which was adapted into an Academy Award-nominated feature film in 1990, starring Robin Williams and Robert De Niro. Nina Salaman, (n15 July 1877 – 22 February 1925) was a British Jewish poet, translator, and social activist. Aside from her original poetry, she is best known for her English translations of medieval Hebrew verse—especially of the poems of Judah Halevi—which she began publishing at the age of 16. Maurice Samuel (1895 – 1972), author of the book You Gentiles, which is controversial for its portrayal of Jews and Gentiles as fundamentally distinct and incompatible civilisations. Samuel's depiction of enduring cultural and psychological differences between the two groups has been described by some critics as implying a form of Jewish supremacy and civilisational separatism.
Sources: en.wikipedia.org
Action & Adventure – The Last of Us Artistic Achievement – Tearaway Audio Achievement - The Last of Us Best Game – The Last of Us British Game – Grand Theft Auto V Debut Game – Gone Home Family – Tearaway Game Design – Grand Theft Auto V Game Innovation – Brothers: A Tale of Two Sons Mobile & Handheld – Tearaway Online Multiplayer – Grand Theft Auto V Original Music – BioShock Infinite Performer – Ashley Johnson (as Ellie, The Last of Us) Sports – FIFA 14 Story – The Last of Us Strategy & Simulation – Papers, Please BAFTA Ones to Watch Award – Size DOES Matter Academy Fellowship – Rockstar Games
== Structure == The appearance of transitional epithelium differs according to its cell layer. Cells of the basal layer are cuboidal (cube-shaped), or columnar (column-shaped), while the cells of the superficial layer vary in appearance depending on the degree of distension. These cells appear to be cuboidal with a domed apex when the organ or the tube in which they reside is not stretched. When the organ or tube is stretched (such as when the bladder is filled with urine), the tissue compresses and the cells become stretched. When this happens, the cells flatten, and they appear to be squamous and irregular.
The process required pressing tungsten powder into bars, then several steps of sintering, swaging, and then wire drawing. It was found that very pure tungsten formed filaments that sagged in use, and that a very small "doping" treatment with potassium, silicon, and aluminum oxides at the level of a few hundred parts per million (so-called AKS tungsten) greatly improved the life and durability of the tungsten filaments. The predominant mechanism for failure in tungsten filaments even now is grain boundary sliding accommodated by diffusional creep. During operation, the tungsten wire is stressed under the load of its own weight and because of the diffusion that can occur at high temperatures, grains begin to rotate and slide. This stress, because of variations in the filament, causes the filament to sag nonuniformly, which ultimately introduces further torque on the filament. It is this sagging that inevitably results in a rupture of the filament, rendering the incandescent lightbulb useless.
Sources: en.wikipedia.org
PT-141 is a research code for bremelanotide, a cyclic peptide that activates melanocortin receptors. It was developed for sexual dysfunction and later approved under a brand name as a subcutaneous injection. The same code is widely used by suppliers selling non-pharmaceutical material.
Both are synthetic melanocortin agonists and share a similar peptide backbone, but they are distinct molecules with different receptor profiles. Melanotan II was never approved as a medicine, whereas bremelanotide was. Findings about one compound should not be transferred to the other without direct evidence.
It is typically distributed as a lyophilized powder in sealed vials, sometimes with a separate solvent. Purity statements usually originate from the supplier rather than an independent laboratory. Storage recommendations vary between vendors, which makes comparison across sources difficult.
PT-141 is a laboratory code for bremelanotide, a synthetic peptide that activates melanocortin receptors. It has been developed both as an injectable pharmaceutical product and as a research chemical. The two contexts differ sharply in how identity, purity, and dosing are controlled.